CRC 11006: Phase I Trial of Intraperitoneal nab-Paclitaxel (Abraxane®) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Type of Study
Cancer (Oncology) - Gynecologic, Cancer (Oncology) - Peritoneal
Location
Swedish Cancer Institute
Short Description

Purpose: This phase I trial is studying the side effects and best dose of intraperitoneal paclitaxel albumin-stabilized nanoparticle formulation in treating patients with advanced cancer of the peritoneal cavity.

Status
Open to Enrollment
Principal Investigator
Saul Rivkin, M.D.
Eligibility Notes
  • Histologically confirmed advanced cancer primarily confined to the peritoneal cavity
    • Refractory to chemotherapy OR disease for which no "standard" chemotherapeutic regimen exists
  • Patients with ovarian cancer who have residual disease at second-look laparotomy or following secondary debulking (performed 4-6 weeks ago) are eligible
  • Measurable disease allowed but not required
  • No known brain metastases
  • . No ongoing abdominal infections or bowel obstruction
  • No known peritoneal adhesions
  • No pre-existing sensory neuropathy ≥ grade 2
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy and recovered
  • Prior taxanes allowed
  • Prior intraperitoneal chemotherapy allowed provided it was not complicated by peritoneal adhesions
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086
Email
CancerResearch@swedish.org
  • Print